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Abstract  
Background: Viral infection of the bronchial epithelium disrupts the barrier properties of the 
epithelium in healthy individuals and those with lung disease. Repair of the bronchial 
epithelium is dependent of the formation of a provisional fibrin matrix and migration of 
epithelial cells to cover denuded areas, followed by proliferation and differentiation.  
Objective: The objective was to test the hypothesis that poly I:C, a model of viral infection, 
limits  epithelial repair through the stimulated release of matrix metalloproteinase-13 
(MMP-13). 
Methods: Confluent layers of cultured normal human primary bronchial epithelial cells 
(NHBE) and SV-40 virus transformed 16HBE14o- bronchial epithelial cells were mechanically 
wounded, and video microscopy used to measure the rate of wound closure over 2 hours, in 
the absence and presence of poly I:C (1-20 µg/ml). MMP-13, tissue factor and endothelin 
release were measured by ELISA. The effect of inhibitors of MMP-13 activity and expression 
and a non-specific endothelin receptor antagonist, bosentan, on the rate of epithelial repair 
was investigated 
Results: Poly I:C limited the rate of epithelial repair, and NHBE were significantly more 
sensitive to poly I:C effects than 16HBE14o- cells. NHBE, but not 16HBE14o-, released MMP-
13 in response to poly I:C.  Inhibitors of MMP-13 activity (WAY 170523) and expression 
(dimethyl fumarate) significantly enhanced the rate of repair.  Bosentan enhanced the rate 
of bronchial epithelial repair by a mechanism that was independent of MMP-13.  
Conclusions and clinical relevance: Bronchial epithelial repair is limited by endothelin and by 
MMP-13, a protease that degrades coagulation factors, such as fibrinogen, and matrix 
proteins essential for epithelial repair. Further studies with primary cells from patients are 
needed to confirm whether repurposing bosentan and inhibitors of MMP-13 expression or 
activity, for inhalation may be a useful therapeutic strategy in diseases where repeated 
cycles of epithelial injury and repair occur, such as asthma and COPD.    
 
Introduction: 
The bronchial epithelium plays a key role in immune responses to the environment, and its 
integrity is paramount in defence against infection, allergens and pollution. Inherited or 
acquired defects in innate defences in asthma and COPD render the bronchial epithelium 
susceptible to environmental factors, with cycles of epithelial damage and repair playing a 
key role in both the initiation and progression of these chronic airways diseases [1, 2]. 
Respiratory viral infections, particularly with rhinovirus (RV), the most prevalent respiratory 
virus, cause exacerbations of asthma and COPD, which in turn are associated with increased 
morbidity and mortality [3, 4]. People with asthma and healthy individuals are equally at risk 
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of upper respiratory tract infection with RV however those with atopic asthma have more 
frequent and more severe lower respiratory tract symptoms [5].  Respiratory viral infections 
cause epithelial barrier disruption that predisposes to antigen sensitisation in asthma [1] 
and bacterial infection in COPD [3, 4].  Therapeutics that improve bronchial epithelial repair 
increase the resistance of the airways to these sequelae, limiting the consequences of viral 
infection as well as other aggravating factors that disrupt the barrier function, such as 
proteolytic allergens, oxidants in cigarette smoke, air pollutants and pro-inflammatory 
cytokines [6].  
Viral infection of the airways activates epithelial cells and disrupts epithelial tight junctions 
and adherens junctions, reducing the barrier function of the bronchial epithelium [7, 8, 9]. 
RNA viruses such as RV and respiratory syncytial virus (RSV) replicating within host cells 
produce double stranded RNA (dsRNA), which is recognised by Toll-like receptor 3 (TLR3) on 
endosomes. TLR3 binding of dsRNA, or a synthetic analogue, polyinosinic:polycytidylic acid 
(poly I:C), induces expression of pro-inflammatory cytokines and disrupts the epithelial 
barrier function in both primary normal human bronchial epithelial cells (NHBE) and the 
16HBE14o- transformed bronchial epithelial cell line  [7,8]. Disruption of the epithelial 
barrier is independent of autocrine or paracrine effects of released cytokines [8,9], but 
reflects direct effects of TLR3 signalling through the TIR-domain-containing adapter-inducing 
interferon-β (TRIF) pathway leading to decreased expression of members of the tight 
junction claudin protein family [7], disruption of the actin cytoskeleton and redistribution of 
tight junction (occludin and ZO-1) and adherens junction (E-cadherin and β-catenin) proteins 
from intercellular contacts to the cytoplasmic compartment without change in expression 
levels [8, 9]. 
It follows that repair of the epithelium is essential for recovery of barrier function. The 
restitution of normal airway epithelium involves the formation of a provisional fibrin matrix 
[10] and migration of neighbouring epithelial cells over the first 12-24 hours to cover 
denuded surfaces as the primary repair mechanism, followed by proliferation of progenitor 
cells to restore cell numbers and differentiation to restore function [11]. Within the airway, 
injury to the epithelium is followed by an inflammatory response involving neighbouring 
epithelial cells, fibroblasts, macrophages, endothelial cells and plasma exudation [11]. The 
released soluble factors supporting epithelial repair include growth factors, cytokines, 
matrikines and MMPs [11]. MMP-1, MMP-7 and MMP-9 are proposed to facilitate epithelial 
repair by promoting cell migration [11]. 
We previously showed that bronchial epithelial repair following mechanical disruption was 
dependent on the local expression of coagulation factors including tissue factor (TF), 
fibrinogen and Factor XIIIA in NHBE and 16HBE14o- cell monolayers and the formation of a 
provisional fibrin matrix [10].  It has been shown that MMP-13 (collagenase-3) impairs fibrin 
formation via degradation of fibrinogen [12] and other coagulation factors [13] as well as 
matrix proteins.  Further, poly I:C as a model of most replicating virus [14] strongly 
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stimulated expression of its receptor (TLR-3), release of pro-inflammatory cytokines, and a 
large 25-fold increase in MMP-13 expression, without change in TIMP-1 or TIMP-2, in small 
airway epithelial cells [15]. We hypothesised a role for MMP-13 in limiting bronchial 
epithelial repair following virus infection, which has not previously been demonstrated.   
We therefore investigated expression of MMP-13 in cultures of the 16HBE14o- bronchial 
epithelial cell line (16HBE) and normal primary bronchial epithelial cells (NHBE) exposed to 
poly I:C as a model of viral infection, the effect of increased expression of MMP-13 on the 
rate of repair following mechanical wounding of confluent bronchial epithelial cell layers, 
and the potential for inhibitors of MMP-13 activity and/or expression to enhance the rate of 
bronchial epithelial repair. 
 
Materials and Methods: 
Cell Culture 
Cells of the SV-40 virus transformed human bronchial epithelial cell line, 16HBE14o-, were 
cultured in minimal essential media (MEM; GibcoBRL, Paisley, UK) containing 10 % heat 
inactivated-foetal calf serum (FCS; Sigma F9665), 2 mM L-glutamine (GibcoBRL) and 1% 
antibiotic/antimycotic (GibcoBRL, 100 units penicillin G, 100 µg streptomycin, 250 ng 
amphotericin B/ml) in 75 cm2 tissue culture grade flasks at 37°C in 5 % CO2. At 80-90 % 
confluence the cells were passaged using 0.05 % trypsin-0.02% EDTA (Sigma 59418C). After 
re-suspending in 1 ml full media the cells were counted and seeded at 100,000 cells per well 
in a 24-well plate, and cultured for 2 days to confluence in 250 µl full medium.  
Normal human bronchial epithelial cells (NHBE) in bronchial epithelial growth medium 
(BEGM) were purchased from Lonza (Basel, CH), and are derived from the bifurcation of the 
trachea, and are therefore a mixture of bronchial and tracheal epithelial cells. Cells were 
grown in 75 cm2 tissue culture grade flasks and sub-cultured at 100,000 cells per well into 
24-well plates, flasks and plates pre-coated with collagen IV at 10 g/cm2, and cultured in 
fully supplemented BEGM (BulletKit: Lonza, CH) at 37C in a 5% CO2 incubator until 
confluent. NHBE cells were used with a maximum of 3 passages and experiments were 
carried out with cells from 3 different donors. 
 
Mechanical wounding  
At confluence, scrape damage was applied using a P200 yellow pipette tip to produce a 
single wound 0.8 mm wide. Cell layers were washed and covered with 250 µl fresh warm 
medium containing 1-20 µg/ml poly I:C (Sigma) [14,15], in the absence and presence of 1 
µM WAY 170523 (Tocris Bioscience) [16,17], 1-50 µM dimethyl fumarate (Sigma) [18] or 
0.01-1 µM bosentan (Sigma) [19], at the concentrations indicated in the legends and on the 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
figures. Control cells were untreated.  Each condition was replicated in triplicate within each 
independent experiment. Damaged cultures were incubated for 24 hours for real-time video 
microscopy (see below).  After 24 hours, supernatants were removed, cell debris cleared 
and supernatants stored at -80°C prior to analysis.   
Video microscopy 
24-well plates were incubated for 24 hours at 37°C with 5% CO2  on the stage of a Zeiss 
Axiovert 200M inverted microscope for live cell imaging.  A 5X objective was used and bright 
field images were acquired every 15 minutes for 24 hours.  Volocity software (Version 6.1; 
Quorum Technologies, Guelph, Ontario) was used to obtain movies for each well and also to 
measure gap distances (µm) across each wound at 5 locations at each time point. Time to 
closure and initial rate of closure over the first two hours as µm/hour were calculated 
(mean±SEM) using MS Excel.  
 
Measurement of total MMP-13, TF and endothelin (ET) in cell culture supernatants; 
Total MMP-13, TF and ET were measured by ELISA using Duo-Sets from R&D Systems 
according to the manufacturer’s instructions.  
MMP-13 standards were added to ELISA plates in the concentration range 62.5-4000 pg/ml, 
and NHBE samples diluted 1:2 for analysis in duplicate.   We determined the lower limit of 
detection for the assay to be 21.91 pg/ml and the intra-assay coefficient of variance to be 
4.9% (n=40). 
TF standards were added to ELISA plates in the concentration range 7.8-500 pg/ml and 
samples diluted 1:2 for analysis in duplicate. We determined the lower limit of detection for 
the assay to be 4.81 pg/ml and the intra-assay coefficient of variance to be 4.8% (n=28). 
ET-1 standards were added to ELISA plates in the concentration range 3.9-250 pg/ml and 
samples diluted 1:2 for analysis in duplicate. We determined the lower limit of detection for 
the assay to be 0.09 pg/ml and the intra-assay coefficient of variance to be 6.4% (n=39). 
 
Statistical analysis 
Statistical analysis was carried out using GraphPad Prism software (Version 7, La Jolla, CA, 
USA). Data for TF were analysed using one-way ANOVA. Data for the effect of WAY 170523, 
DMF and bosentan on the rate of epithelial repair were analysed by two-way ANOVA with 
Bonferroni’s correction for multiple comparisons. 
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Results 
Poly I:C significantly inhibited the initial rate of repair of both the bronchial epithelial cell 
line and  primary NHBE cells (Figure 1).  Poly I:C had a significantly greater effect and was at 
least an order of magnitude more potent at inhibiting wound repair in NHBE cultures over 2 
hours (Figure 1B) and 24 hours (Figure 2) compared to 16HBE cultures (Figure 1A). Over 24 
hours the wounded 16HBE cell layers had completely repaired in the absence or presence of 
poly I:C.  However, although wounded NHBE layers cultured in media alone for 24 h were 
largely restored to confluence (Figure 2D), in the presence of 20 µg/ml poly I:C cells were 
scattered and the wound failed to heal (Figure 2E). 
We investigated the effect of a specific inhibitor of MMP-13 activity, WAY 170523, on the 
epithelial repair response in the presence of poly I:C.  Results (Figure 1A and B) show that in 
the presence of WAY 170523 (1 µM) there was no effect of poly I:C on the rate of epithelial 
repair, and that  WAY 170523 significantly inhibited the effect of poly I:C (20 µg/ml and 1 
µg/ml) in 16HBE and NHBE epithelial cell models, respectively.  
We subsequently investigated whether the increased sensitivity of NHBE to poly I:C was due 
to higher levels of MMP-13 in NHBE compared to 16HBE cell cultures.  Figure 3 shows that 
NHBE constitutively express and release MMP-13 into cell culture supernatants (1203±222.3 
pg/ml at baseline).  MMP-13 levels were stimulated by poly I:C in a concentration-
dependent manner  and were significantly increased above baseline on incubation with 10-
20 µg/ml poly I:C (4133±159 pg/ml with 20 µg/ml poly I:C).  Conversely, concentrations of 
MMP-13 in 16HBE14o- cell supernatants were below the lower limit of detection. 
In view of the evidence that MMP-13 activity (Figure 1) limits the rate of bronchial epithelial 
repair in the cell cultures, we next investigated the effect of dimethyl fumarate (DMF), an 
inhibitor of MMP-13 expression in chondrocytes in the range 1-50 µM [18]. In the same 
concentration range DMF inhibited poly I:C-induced MMP-13 expression, with a significant 
50% inhibition of MMP-13 in the presence of 20 µg/ml poly I:C, from 4133±159 to 2068±743 
pg/ml (Figure 3).  
In the same concentration range DMF alone had no effect on the rate of repair of 16HBE cell 
layers, but at 10-50 µM, DMF significantly enhanced the rate of epithelial repair in the 
presence of 20 µg/ml poly I:C (Figure 4A). Further, the repair of NHBE monolayers strongly 
inhibited by poly I:C in the concentration range 1-20 µg/ml, was restored by DMF (50 µM) at 
all concentrations of poly I:C (Figure 4B). 
In view of our previous findings demonstrating an important role for coagulation in 
bronchial epithelial repair, initial experiments investigated the effect of poly I:C on TF 
protein expression over 24 hours (Figure 5). Wounding alone had no significant effect on TF 
antigen levels in supernatants, as we had previously observed [10], but poly I:C at 10 and 20 
µg/ml stimulated a significant increase in TF in both intact and wounded 16HBE cell layers 
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(Figure 5A). However, poly I:C had no effect on TF protein expression in wounded NHBE cell 
layers at any concentration (Figure 5B). 
 
The non-specific endothelin receptor antagonist, bosentan (1-10 µM), was previously shown 
to inhibit MMP-13 release from primary bronchial epithelial cells stimulated with TNFα [19]. 
We therefore investigated the effect of poly I:C on endothelin release from NHBE (Figure 
6A) and the effect of bosentan of the rate of NHBE repair (Figure 6B). 
 
Poly I:C stimulated a significant increase in the release of endothelin (Figure 6A).  Bosentan 
in the concentration range 10-1000 nM potently and effectively reversed the inhibitory 
effect of poly I:C (20 µg/ml) on the rate of NHBE repair (Figure 6B). However, bosentan in 
the concentration range 10-1000 nM had no effect on MMP-13 release from NHBE (n=3, not 
shown) and, conversely, exogenously added endothelin-1 (1 – 100 nM) did not stimulate 
MMP-13 release (not shown).       
 
Discussion 
This is the first report that epithelial-derived MMP-13 limits epithelial repair, that poly I:C 
significantly increases MMP-13 release from mechanically wounded NHBE and that 
inhibitors of MMP-13 activity and expression enhance bronchial epithelial repair.  Our study 
also shows that factors supporting fibrin formation, namely significantly increased TF and 
limited MMP-13 release, render 16HBE cells relatively resistant to the effects of poly I:C on 
the rate of bronchial epithelial repair compared to NHBE.  
The difference in the effect of poly I:C on the repair response in 16HBE and NHBE cell-based 
models was striking.  Although poly I:C inhibited the rate of cell migration and wound repair 
in both cell types, NHBE were significantly more sensitive to the effect of poly I:C (Figures 1 
and 2). This may partly reflect the significantly increased expression of TF, a coagulation 
factor essential for epithelial repair [10], in the 16HBE cells, but not in the NHBE cells, in 
response to poly I:C.  The difference in the rate of repair may also reflect significant poly I:C 
induced MMP-13 expression in NHBE cells (Figure 3), but not in 16HBE cells in which MMP-
13 expression remained low.  MMP-13 expression is positively regulated by BCYRN1, a c-
MYC-activated long non-coding RNA, in non-small-cell lung cancer cells [20].  Expression of 
BCYRN1 is extremely low in the 16HBE cell line, which may account for the low levels of 
MMP-13 released from these cells [20]. BCYRN1 is generally not detected in normal tissue 
[20] and physiological expression of MMP-13 is limited to tissues undergoing rapid 
extracellular matrix remodelling [13]. Overall, the data indicate that the 16HBE cell line, 
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although widely used, may not be a suitable model to measure the rate of normal bronchial 
epithelial repair. 
Targets for MMP-13 include type I, II,III, IV, X, XIV collagens, tenascin C, aggrecan core 
protein, perlecan, fibronectin, fibrinogen, factor XII, fibrillin and fibrillin-rich microfibrils, as 
well as the serpins PAI-2 and α2-antichymotrypsin [13]. We previously showed that normal 
bronchial epithelial repair following mechanical wounding is dependent on coagulation 
factor expression and fibrin formation [10].  In our model of normal bronchial epithelial 
repair following viral infection, increased MMP-13 activity is proposed to degrade 
coagulation factors and matrix proteins essential for successful epithelial repair.  The MMP-
13 inhibitor WAY 170523 significantly enhanced the rate of repair of NHBE cell layers, 
suggesting a potent inhibitory effect of MMP-13 activity on normal bronchial epithelial 
repair. 
Secretion of MMP-13 was previously shown to be strongly induced by poly I:C acting on 
small airway epithelial cells [15], an effect mediated via release of IFN-β and interferon 
receptor pathways [21].  Increased expression of MMP-13 was also reported in primary 
tracheobronchial airway epithelial cells infected with both respiratory syncytial virus and 
influenza A [22]. Together with our findings in NHBE, increased expression and release of 
MMP-13 may be common to viral infection of epithelial cells throughout the respiratory 
tract. Increased MMP-13 expression in alveolar macrophages and type II pneumocytes in 
COPD [23] and the recently reported role of MMP-13 in lung destruction in a viral 
exacerbation model of COPD [24], together with increased MMP-13 gene expression in the 
upper and lower respiratory tract epithelium in response to viral infection in asthma [25, 26] 
which is not different to the normal response, suggest that targeting MMP-13 may be a 
viable treatment option in both of these diseases. 
Inhibitors of MMP-13 activity, including selective inhibitors [27, 28] and specific neutralising 
antibodies [29] that avoid the side effects of broad spectrum MMP inhibitors are currently 
in development for the treatment of arthritis, cancer and cardiac disease, with the potential 
for repurposing for respiratory disease.  Other approaches include inhibition of MMP-13 
expression. DMF was previously shown to attenuate MMP-13 expression in isolated 
chondrocytes by inhibiting the JAK/STAT3 pathway [18].  Our results provide evidence that 
DMF similarly attenuates MMP-13 expression in bronchial epithelial cells and has a positive 
effect on epithelial repair.  DMF was originally developed to treat inflammatory skin disease 
such as psoriasis and was recently repurposed to treat multiple sclerosis [30]. Others 
recently proposed repurposing DMF as an anti-inflammatory therapy for asthma [31] and 
we now suggest that DMF may also limit inflammation indirectly through positive effects on 
bronchial epithelial repair. 
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Of particular further interest are the recent reports that the leukotriene receptor antagonist 
montelukast not only suppresses inflammation in a poly I:C-induced asthma exacerbation 
model in mice  [32], but also suppresses LPS-induced MMP-13 expression in mouse 
osteoblasts [33]. However, the effects of montelukast on bronchial epithelial repair in our 
model remain to be investigated. 
Bosentan was previously shown to inhibit MMP-13 release from primary bronchial epithelial 
cells stimulated with TNFα [19].  However, although we demonstrated that poly I:C (20 
µg/ml) induced endothelin release from NHBE (Figure 6A), the positive effect of bosentan 
on the rate of epithelial repair in the presence of poly I:C (20 µg/ml) was not related to 
inhibition of MMP-13 release.  Alternatively, endothelin-1 was previously shown to result in 
slower migration of primary bronchial epithelial cells across uncoated filters [34].  In our 
experiments, the strong positive effect of bosentan on epithelial repair in the presence of 
poly I:C may reflect inhibition of endogenously produced endothelin-1 acting in an autocrine 
fashion on endothelin receptors A and/or B expressed on primary bronchial epithelial cells 
[35] to limit the rate of cell migration. Figure 7 illustrates our proposed mechanisms for 
defective bronchial epithelial repair following virus infection, identifying targets and drugs 
to improve repair.   
Endothelin-1 is a potent bronchoconstrictor and pro-inflammatory mediator that plays a 
role in the pathogenesis of lung diseases, including asthma, and in the co-morbidities 
associated with COPD [36].  A role for endothelin receptor antagonists and the repurposing 
of bosentan, approved for pulmonary arterial hypertension, for asthma was proposed [37]. 
Although treatment with oral bosentan for 4 weeks did not improve lung function or 
symptom score in difficult to control asthma [38], it was suggested that local delivery via 
inhalation may enhance the potency and efficacy of repurposed drugs for allergy and 
asthma, while avoiding the systemic adverse side effects [37].  Animal models have 
indicated the feasibility of this approach for bosentan [39, 40]. 
The limitations of the study that influence the final conclusions are that analysis was done 
only in normal NHBE and the results have yet to be confirmed in diseased cells. Additionally, 
the results were not confirmed in differentiated epithelial cells, using the air-liquid interface 
(ALI) model. However, others [41] have shown that NHBE in ALI close by only 20% even at 48 
hours, which was suggested to be due to technical issues with using ALI for wound repair 
assays.  
Overall, the mechanisms by which respiratory viruses limit the repair response are not well 
understood and this is an important research area for identifying therapeutic targets aimed 
at enhancing epithelial repair. Chronic airways diseases such as asthma and COPD are 
associated with repeated cycles of injury and repair.  Derangements in bronchial epithelial 
function may contribute to epithelial fragility and airway remodelling [42] and the 
epithelium is therefore a particular target for focused therapeutic interventions in asthma 
[43, 44] and COPD [2].  Overall, our results lead us to propose a novel MMP-13-dependent 
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mechanism for defective bronchial epithelial repair following virus infection.  However, 
further studies using primary cells from patients are needed to confirm whether MMP-13 
inhibitors and endothelin receptor antagonists repurposed for inhalation may be useful 
therapeutic approaches in asthma and COPD. 
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Figure legends 
Figure 1. The effect of poly I:C  and the MMP-13 inhibitor, WAY 170523, on bronchial 
epithelial repair. Poly I:C (black bars) limits the rate of epithelial wound repair, and WAY 
170523 (1 µM) restores the rate of repair (grey bars) in (A) 16HBE cells (n=8) and (B) NHBE 
(n=3 or 4). * p<0.05, ** p<0.01, *** p<0.001 compared with the no poly I:C control.    p<0.05 
compared to poly I:C alone. 
 
Figure 2. Confluent NHBE layers wounded mechanically with a pipette tip (A) were analysed 
using video microscopy over 24 h, with recordings made every 15 minutes. Wounds starting 
to repair in media alone at 2 h (B) failed to start repair in the presence of 20 µg/ml poly I:C 
at 2 h (C). Cell layers cultured in media alone for 24 h were largely restored to confluence 
(D) but in the presence of 20 µg/ml poly I:C cells were scattered and the wound failed to 
heal (E). Image width = 1707 µm. 
Figure 3. MMP-13 expression in NHBE. A. Poly I:C (black bars) increases expression and 
release of MMP-13 from NHBE, while 50 µM DMF (grey bars) inhibits expression and release 
of MMP-13 from NHBE stimulated with 20 µg/ml poly I:C. * p<0.05, ** p<0.01 compared 
with the no poly I:C control.   p<0.05 compared to poly I:C alone (n=3).    
Figure 4. DMF enhances bronchial epithelial repair.  A. DMF alone (black bars) had no effect 
on the rate of epithelial repair in 16HBE cells, but in the presence of 20 µg/ml poly I:C (grey 
bars) DMF at 10 µM and 50 µM significantly enhances the rate of repair compared to the 
effect of poly I:C alone. * p<0.05, ** p<0.01 compared with DMF alone.   p<0.05 compared 
to poly I:C alone, (n=3).   B. Poly I:C (1-20 µg/ml) alone (black bars) inhibits the rate of NHBE 
repair and addition of 50 µM DMF (grey bars) significantly reversed the effect of poly I:C at 
all concentrations tested. **p<0.01 compared to the no poly I:C control.  p<0.05, 
p<0.01 compared to the poly I:C alone control (n=3 or 4). 
Figure 5. The effect of poly I:C on TF release by bronchial epithelial cell layers. Poly I:C 
strongly stimulated TF release from intact and wounded 16HBE bronchial epithelial cell 
layers, ** p<0.01, *** p<0.001 compared with the no poly I:C control (n=4). Poly I:C had no 
effect on TF release from wounded NHBE cell layers (n=4).     
Figure 6. The effect of endothelin-1 on NHBE repair. A. Poly I:C (20 µg/ml) induces 
endothelin-1 release in NHBE. B. Poly I:C (grey bars) alone (20 µg/ml) completely inhibits 
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NHBE repair. The dual endothelin receptor antagonist bosentan, at 10-1000 nM, reverses 
the inhibitory effect of 20 µg/ml poly I:C on NHBE repair responses.  ** p<0.01, *** p<0.001 
compared to the no poly I:C control,  p<0.01,  p<0.001 compared to the poly I:C 
alone control (n=3). 
Figure 7.  Proposed mechanisms for defective bronchial epithelial repair following virus 
infection, identifying targets and drugs to improve repair.  TLR-3 activation with poly I:C 
increases endothelin-1 (ET-1) and MMP-13 release from NHBE. ET-1 is proposed to limit the 
repair response through direct effects on cell migration, and these effects can be blocked by 
the dual ET-1 receptor antagonist bosentan.  MMP-13 is proposed to limit repair through 
degradation of coagulation factors and matrix proteins, including fibrinogen, which are 
essential for epithelial repair. Inhibitors of MMP-13 activity (WAY170523) and expression 
(DMF) therefore improve the repair response in the presence of poly I:C. 
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